Gilardoni has entered into an exclusive distribution partnership with Precision X-Ray for the RADGIL2 X-ray blood irradiator in the US.

RADGIL2 is designed to X-ray irradiation of blood and blood components safely and effectively.

This is crucial for preventing diseases such as Transfusion-associated Graft versus Host Disease (TA-GvHD).

The irradiator also offers a safer and more efficient alternative to traditional irradiators that use Cesium-137.

It has the capacity to hold up to six blood products and features an easy-to-load single canister, a syringe holder and a pre-set dose indication.

RADGIL2 delivers a 25Gy central dose in under five minutes and incorporates an integrated data management system.

Its high dose rate and rotating canister technology allow for rapid dose delivery, significantly reducing the time needed for blood irradiation procedures. This ensures a precise and uniform dose distribution.

Precision CEO Viktoriya Baytser said: “We, at Precision, are proud and thrilled to partner with Gilardoni to deliver the RADGIL2 blood irradiator in the US.

“This strategic collaboration will immediately expand our presence in the medical field, while underscoring our long-term dedication to advancing state of the art X-ray irradiators and delivering safer, more reliable and more effective solutions for critical applications including blood irradiation.”

Gilardoni CEO Marco Gilardoni said: “We are delighted to be partnering with a company with [a] highly valued and trusted brand in the X-ray irradiation market. Precision shares our commitment to improving the standard of care for blood irradiation. The Gilardoni team is excited to work together with Precision to establish the RADGIL2 as the new standard for blood irradiation in the US.”

RADGIL2 has received clearance from the US Food and Drug Administration and is available for use in the US and Canada.